Invasive pneumococcal disease in Argentina: a snapshot from a retrospective observational study on serotypes, antimicrobial resistance, and the potential impact of the COVID-19 pandemic (2018-2022)

阿根廷侵袭性肺炎球菌疾病:一项关于血清型、抗菌素耐药性和 COVID-19 大流行潜在影响的回顾性观察研究(2018-2022 年)概览

阅读:1

Abstract

BACKGROUND: Streptococcus pneumoniae is a leading cause of morbidity and mortality and poses a significant public health threat globally. This study aimed to characterise changes in serotype distribution, in vitro antimicrobial susceptibility, and the frequency of invasive pneumococcal disease (IPD) in paediatric and adult populations in Argentina during the pre-COVID (2018-2019) and post-COVID (2021-2022) eras. METHODS: We conducted a national laboratory-based surveillance study analysing 1304 S. pneumoniae isolates sourced from Argentina's National Surveillance Program for invasive pneumococcal disease. Isolates were stratified by age and serotype, with antimicrobial susceptibility evaluated where applicable. FINDINGS: A significant decrease in isolates was observed in 2020, followed by a resurgence beginning in 2021, peaking in 2022. The most prevalent serotypes in children (<5 years) over the past five years included 3 (11%; 54/494), 24F (8%; 39/494), 19A (7%; 35/494), 12F (6%; 30/494), and 14/23B (4%; 20/494). In adults (≥18 years), the leading serotypes were 3 (17%; 92/542), 8 (14%; 76/542), 7F (5%; 27/542), 9N (4%; 22/542), and 19A (4%; 22/542). Notably, antimicrobial resistance levels were significant, with children showing higher resistance rates (26% multidrug resistance) compared to adults (8%), Among PCV13 serotypes, 19A was predominantly associated with multidrug resistance, while non-PCV13 serogroup 24 was prevalent among resistant isolates. INTERPRETATION: The fluctuations in serotype circulation, particularly among children under five, suggest evolving dynamics post-COVID-19. Although it remains uncertain if these changes are directly linked to the pandemic or reflect broader trends, the data highlight an urgent need for continued surveillance and potential adaptations in vaccination strategies. FUNDING: No funding was received for this study.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。